Mirae Asset Global Investments Co., Ltd. Protagonist Therapeutics, Inc Transaction History

Mirae Asset Global Investments Co., Ltd.

$24 Billion
Q4 2024

A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 1,986 shares of PTGX stock, worth $76,798. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,986

Previous 2,130 6.76%

Holding current value

$76,798

Previous $95,000 20.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 27, 2025	SELL	$38.51 - $48.43 $5,545 - $6,973	-144 Reduced 6.76%	1,986 $76,000
Q3 2024 Oct 23, 2024	BUY	$33.72 - $47.33 $12,779 - $17,938	379 Added 21.64%	2,130 $95,000
Q2 2024 Jul 30, 2024	SELL	$24.66 - $34.8 $685,720 - $967,683	-27,807 Reduced 94.08%	1,751 $60,000
Q1 2024 May 01, 2024	SELL	$21.79 - $32.15 $47,959 - $70,762	-2,201 Reduced 6.93%	29,558 $855,000
Q4 2023 Jan 24, 2024	SELL	$14.05 - $23.44 $76,755 - $128,052	-5,463 Reduced 14.68%	31,759 $728,000
Q3 2023 Oct 26, 2023	BUY	$16.68 - $23.66 $25,937 - $36,791	1,555 Added 4.36%	37,222 $620,000
Q2 2023 Aug 10, 2023	BUY	$18.02 - $29.36 $144,844 - $235,995	8,038 Added 29.09%	35,667 $985,000
Q1 2023 May 04, 2023	BUY	$10.78 - $25.38 $83,566 - $196,745	7,752 Added 39.0%	27,629 $635,000
Q4 2022 Feb 09, 2023	BUY	$7.36 - $11.17 $147 - $223	20 Added 0.1%	19,877 $216,000
Q3 2022 Nov 10, 2022	BUY	$7.86 - $11.71 $46,641 - $69,487	5,934 Added 42.62%	19,857 $167,000
Q2 2022 Jul 26, 2022	BUY	$7.06 - $25.52 $98,296 - $355,314	13,923 New	13,923 $110,000

Others Institutions Holding PTGX

# of Institutions

254

Shares Held

58.9M

Call Options Held

189K

Put Options Held

191K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $1.9B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.

Account

Mirae Asset Global Investments Co., Ltd. Protagonist Therapeutics, Inc Transaction History